Injection-Based Administration Subcutaneous injections: All GLP-1 RAs are administered via subcutaneous injection Prefilled pens: Most common delivery system, allows for self-administration Auto-injectors: Simplify the process for patients with dexterity issues Multi-dose pens: Require dose dialing and needle attachment Dosing frequency: Daily: Liraglutide (Saxenda, Victoza), some formulations of exenatide (Byetta) Weekly: Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide extended-release (Bydureon) Titration schedules: Most FDA-approved GLP-1 RAs require gradual dose escalation to minimize gastrointestinal side effects
Description Cagrilintide Research Peptide (10 mg) Cagrilintide is a synthetic, long-acting amylin analogue engineered through extensive structural modification of human islet amyloid polypeptide (hIAPP, amylin), a 37-amino acid peptide co-secreted with insulin from pancreatic -cells
For the best results, maintain a healthy diet, exercise regularly, and follow a balanced lifestyle
Four capsules is 4 250 = 1,000 mcg , or 1 mg (1 mg = 1,000 mcg)
